The Mycoses drugs in development market research report provides comprehensive information on the therapeutics under development for Mycoses, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Mycoses. Buy the report here.
Smarter leaders trust GlobalData
The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Mycoses and features dormant and discontinued products.
GlobalData tracks 164 drugs in development for Mycoses by 128 companies/universities/institutes. The top development phase for Mycoses is preclinical with 87 drugs in that stage. The Mycoses pipeline has 134 drugs in development by companies and 30 by universities/ institutes. Some of the companies in the Mycoses pipeline products market are: Pulmonomy, Satellos Bioscience and University of Wisconsin Madison.
The key targets in the Mycoses pipeline products market include Lanosterol 14 Alpha Demethylase (Sterol 14 Alpha Demethylase or Cytochrome P450 14DM or Cytochrome P450LI or Cytochrome P450 51A1 or CYPLI or CYP51A1 or EC 1.14.14.154), Ergosterol , and Cell Membrane.
The key mechanisms of action in the Mycoses pipeline product include Lanosterol 14 Alpha Demethylase (Sterol 14 Alpha Demethylase or Cytochrome P450 14DM or Cytochrome P450LI or Cytochrome P450 51A1 or CYPLI or CYP51A1 or EC 1.14.14.154) Inhibitor with 16 drugs in Pre-Registration. The Mycoses pipeline products include 14 routes of administration with the top ROA being Topical and 16 key molecule types in the Mycoses pipeline products market including Small Molecule, and Monoclonal Antibody.
Mycoses overview
Mycoses, also known as fungal infections, encompass a diverse group of diseases caused by fungi. These infections can affect various tissues in the body, including the skin, nails, and internal organs. Superficial mycoses, like athlete’s foot and ringworm, involve the outer layers, while systemic mycoses can affect deeper tissues and may be more severe, particularly in individuals with weakened immune systems. Candidiasis is another common example, involving the overgrowth of the Candida yeast. Antifungal medications, both topical and systemic, are used for treatment. Prevention involves good hygiene practices and managing underlying conditions that may compromise the immune system.
For a complete picture of Mycoses’s pipeline drug market, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.
